Literature DB >> 15845499

Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.

Y Al-Mazrou1, M Khalil, R Borrow, P Balmer, J Bramwell, G Lal, N Andrews, M Al-Jeffri.   

Abstract

An immunization campaign with meningococcal ACYW135 polysaccharide vaccine was conducted in 2003 by the Saudi Arabian Ministry of Health and included a study to evaluate the immune responses in children under 5 years of age in the Al Qassim region of Saudi Arabia. Children who were >/=24 months old were given one dose of tetravalent polysaccharide vaccine, while younger children were given two doses with an interval of 2 to 3 months. Blood samples were collected prevaccination and 1 month after the second dose for children younger than 24 months old and 1 month after the single dose for older children. Serogroup-specific antibody responses were determined by serum bactericidal antibody (SBA) assays and a tetraplex immunoglobulin G (IgG) bead assay. Significant increases in the proportions of individuals who were >/=24 months old with SBA titers of >/=8 were observed pre- to postvaccination for all serogroups. Age-dependent increases in the percentage of individuals with SBA titers of >/=8 1 month postvaccination were observed for each serogroup. Age-dependent increases in postvaccination IgG levels were observed for serogroup A (menA), serogroup W135 (menW), and serogroup Y (menY) but not for serogroup C (menC). Two doses of tetravalent polysaccharide vaccine in individuals who were </=18 months old were poorly immunogenic for menC, menW, and menY. However, for menA, 42% of the children who were 18 months old were putatively protected with SBA titers of >/=8. A high percentage of subjects who were >/=2 years of age were putatively protected for menA; a similar level was observed for menY for children who were 4 years of age but not for younger children. However, for menC and menW poor levels of putative protection were still evident at 4 years of age.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845499      PMCID: PMC1087384          DOI: 10.1128/IAI.73.5.2932-2939.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Serogroup W135 meningococcal disease in Hajj pilgrims.

Authors:  M K Taha; M Achtman; J M Alonso; B Greenwood; M Ramsay; A Fox; S Gray; E Kaczmarski
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

2.  Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger.

Authors:  Muhamed-Kheir Taha; Isabelle Parent Du Chatelet; Martin Schlumberger; Idrissa Sanou; Saacou Djibo; François de Chabalier; Jean-Michel Alonso
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Pilgrimage to Mecca (Hajj) 1992.

Authors: 
Journal:  Commun Dis Rep CDR Wkly       Date:  1992-03-06

4.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

5.  Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children.

Authors:  M L Lepow; J Beeler; M Randolph; J S Samuelson; W A Hankins
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

6.  Meningococcal disease and travel.

Authors:  Ziad A Memish
Journal:  Clin Infect Dis       Date:  2001-11-20       Impact factor: 9.079

7.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

8.  Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.

Authors:  P De Wals; G De Serres; T Niyonsenga
Journal:  JAMA       Date:  2001-01-10       Impact factor: 56.272

9.  Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.

Authors:  R Borrow; P Richmond; E B Kaczmarski; A Iverson; S L Martin; J Findlow; M Acuna; E Longworth; R O'Connor; J Paul; E Miller
Journal:  FEMS Immunol Med Microbiol       Date:  2000-05

10.  Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.

Authors:  N E MacDonald; S A Halperin; B J Law; B Forrest; L E Danzig; D M Granoff
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

View more
  8 in total

1.  Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Authors:  Helen Findlow; Samba Sow; Ray Borrow; Milagritos Tapia; Fadima Cheick Haidara; Adebayo K Akinsola; Olubukola T Idoko; Fatoumata Diallo; Richard Adegbola; Yuxiao Tang; Varsha Parulekar; Helen Chadha; Lesley Mabey; Daniel Holme; Kelly Townsend; Julie Chaumont; F Marc Laforce; Prasad S Kulkarni; Elisa Marchetti; Simonetta Viviani; Musa Hassan-King; Marie-Pierre Preziosi
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

2.  Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age.

Authors:  M Khalil; Y Al-Mazrou; P Balmer; J Bramwell; N Andrews; R Borrow
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

3.  Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009.

Authors:  Caroline L Trotter; Helen Findlow; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

4.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

5.  Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.

Authors:  Mohamed Khalil; Yagob Al-Mazrou; Helen Findlow; Helen Chadha; Valerie Bosch Castells; David R Johnson; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2012-08-01

6.  Investigation of correlates of protection against pharyngeal carriage of Neisseria meningitidis genogroups W and Y in the African meningitis belt.

Authors:  Laura V Cooper; Rahamatou Moustapha Boukary; Abraham Aseffa; Wude Mihret; Jean-Marc Collard; Doumagoum Daugla; Abraham Hodgson; Cheikh Sokhna; Babatunji Omotara; Samba Sow; Stephen Laryea Quaye; Kanny Diallo; Olivier Manigart; Martin C J Maiden; Helen Findlow; Ray Borrow; James M Stuart; Brian M Greenwood; Caroline L Trotter
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 7.  Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines.

Authors:  Chakkumkal Anish; Michel Beurret; Jan Poolman
Journal:  NPJ Vaccines       Date:  2021-12-10       Impact factor: 7.344

Review 8.  Vaccination strategies for the prevention of meningococcal disease.

Authors:  Scott Vuocolo; Paul Balmer; William C Gruber; Kathrin U Jansen; Annaliesa S Anderson; John L Perez; Laura J York
Journal:  Hum Vaccin Immunother       Date:  2018-04-13       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.